GlassScriptPhysician profile
Matthew Alan Potts
NPI 1003483702
$4,286.43
in general payments reported to CMS, 2019-2025
38 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $482 · 2023: $1,280 · 2024: $914 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,524.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $826.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $644.23 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $473.27 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $403.01 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.27 | 2022-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $199.34 | 2024-2025 | Venaseal, Intellis Adaptivestim, Minimed 780g |
| Janssen Pharmaceuticals, INC | $156.81 | 2022-2023 | Spravato |
| W. L. Gore & Associates, INC. | $134.99 | 2021 | |
| Alkermes, INC. | $129.07 | 2021-2025 | Vivitrol, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $123.96 | 2023-2024 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $123.91 | 2023 | Camzyos |
| Astellas Pharma US INC | $89.65 | 2024-2025 | Veozah |
| Pfizer INC. | $60.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $53.56 | 2023 | Verquvo, Belsomra, Steglatro |
| Sumitomo Pharma America, INC. | $50.00 | 2025 | Myfembree |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.